Overview

Safety and Efficacy of the Combination of Diacerein 100 mg Daily and MTX Versus MTX Alone in the Treatment of Early Rheumatoid Arthritis (RA)

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of Diacerein 100 mg daily versus placebo in reducing rheumatoid arthritis symptoms, when added to stable oral MTX therapy in patients with active early RA. To evaluate the safety of Diacerein 100 mg daily when administrated in combination with oral MTX therapy in those patients for up to 24 weeks To investigate a potential persistent effect, 4 weeks after Diacerein treatment is stopped (carry-over effect)

Phase:

Phase 2

Details

Lead Sponsor:

TRB Chemedica

Treatments:

Diacetylrhein